Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort
about
The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.Pharmaceutical care outcomes in an outpatient human immunodeficiency virus treatment center in Jos, NigeriaPotential drug-drug interactions on in-patient medication prescriptions at Mbarara Regional Referral Hospital (MRRH) in western Uganda: prevalence, clinical importance and associated factors.Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda.Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infectionClinically significant interactions between antiretroviral and co-prescribed drugs for HIV-infected children: profiling and comparison of two drug databases.Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International ScalePotential drug-drug interactions in HIV-infected children on antiretroviral therapy in Lagos, Nigeria.Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting.Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.Comparing the Frequencies of Contraindicated Drug-Drug Interactions Between Differing Antiretroviral Regimens in HIV-Infected Patients.Associated factors of drug-drug interactions of highly active antiretroviral therapy: report from a referral center.Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary team.Oropharyngeal Candidosis in HIV-Infected Patients-An Update.British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015
P2860
Q33705883-5C2E867F-32FF-400B-8DF2-C8BBC3E6E8E1Q34162556-2DB3A94B-297C-4707-80C6-E2B8C4BF2251Q35680034-EB1F89CB-F256-40A1-9F84-E05405AE1F2EQ36298965-6C578989-557A-4957-813B-4FF78FE303F2Q36320042-B3D4A06E-0513-42DE-A77B-4154E81D44ECQ36863063-70B426B7-32FC-4056-B012-DC733F5C3972Q37245869-45017C1D-FB48-4DF7-8477-440E0A386E80Q37696834-C610AB33-EC67-43A6-9455-91EE464AD751Q38037008-6E36A8D1-8610-4905-81DA-7306E9D93781Q39418438-8951C34E-299C-4496-A3C9-F40B82D241CEQ40262860-8E9576F6-9F96-4BA0-84B5-95B668C22408Q41564295-C4C1A88F-C8D0-47F3-B018-6A9168907ACCQ47407447-58EF268D-5B1B-4245-8128-EA50F0639A1DQ55371002-5DC14034-7640-4CEC-B911-9F34FEEA7E5BQ57180790-673F973B-151D-4F65-8B35-B515EE004F80
P2860
Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Prevalence of potential drug-d ...... drugs in a large Kenyan cohort
@ast
Prevalence of potential drug-d ...... drugs in a large Kenyan cohort
@en
Prevalence of potential drug-d ...... drugs in a large Kenyan cohort
@nl
type
label
Prevalence of potential drug-d ...... drugs in a large Kenyan cohort
@ast
Prevalence of potential drug-d ...... drugs in a large Kenyan cohort
@en
Prevalence of potential drug-d ...... drugs in a large Kenyan cohort
@nl
prefLabel
Prevalence of potential drug-d ...... drugs in a large Kenyan cohort
@ast
Prevalence of potential drug-d ...... drugs in a large Kenyan cohort
@en
Prevalence of potential drug-d ...... drugs in a large Kenyan cohort
@nl
P2093
P2860
P3181
P1433
P1476
Prevalence of potential drug-d ...... drugs in a large Kenyan cohort
@en
P2093
Beatrice Jakait
Brian Faragher
David Back
Edwin Sang
Sara Gibbons
Saye H Khoo
Sylvester Kimaiyo
Winstone Nyandiko
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0016800
P407
P577
2011-02-23T00:00:00Z